棘白菌素与氟康唑治疗尿路来源念珠菌血症的倾向评分分析
多中心研究纳入2176例念珠菌血症成人患者,其中128例(5.88%)为尿路来源念珠菌血症(CUTS)。急性肾衰竭是临床失败的独立危险因素(AOR 3.01),早期尿路引流操作具保护作用(AOR 0.08)。
要点
- 尿路来源念珠菌血症中棘白菌素与氟康唑临床失败率无显著差异。
- 急性肾衰竭与临床失败独立相关(AOR 3.01,95%CI 1.01-8.91)。
核心结论
- 初始棘白菌素治疗与尿路来源念珠菌血症患者的临床失败无关。
- 急性肾衰竭预测更差结局,而早期泌尿外科操作是保护性措施。
研究设计与样本
- 多中心研究,纳入9家医院成年念珠菌血症患者。
- CUTS定义为同一微生物所致念珠菌血症伴念珠菌尿且合并显著泌尿系统合并症。
- 共2176例念珠菌血症,其中128例(5.88%)为CUTS。
- 采用倾向评分计算并纳入回归模型比较棘白菌素与氟康唑治疗结局。
主要发现
- CUTS主要病原体为白色念珠菌(52.7%),其次为光滑念珠菌(25.6%)和热带念珠菌(16.3%)。
- 单因素和多因素分析均未显示棘白菌素治疗改变临床失败风险。
临床怎么用
- 尿路来源念珠菌血症可考虑使用棘白菌素或氟康唑治疗。
- 应关注并管理急性肾衰竭以改善预后。
- 早期行泌尿外科引流操作可能改善尿路来源念珠菌血症结局。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether echinocandins could be used to treat candidemia of a urinary tract source (CUTS) is unknown. We aimed to provide current epidemiological information of CUTS and to compare echinocandin to fluconazole treatment on CUTS outcomes. METHODS: A multicenter study of adult patients with candidemia was conducted in 9 hospitals. CUTS was defined as a candidemia with concomitant candiduria by the same organism associated with significant urological comorbidity. The primary outcome assessed was clinical failure (defined by 7-day mortality or persistent candidemia) in patients treated with either an echinocandin or fluconazole. A propensity score was calculated and then entered into a regression model. RESULTS: Of 2176 episodes of candidemia, 128 were CUTS (5.88%). Most CUTS cases were caused by Candida albicans (52.7%), followed by Candida glabrata (25.6%) and Candida tropicalis (16.3%). Clinical failure occurred in 7 patients (20%) treated with an echinocandin and in 15 (17.1%) treated with fluconazole (P = .730). Acute renal failure (adjusted odds ratio [AOR], 3.01; 95% confidence interval [CI], 1.01-8.91; P = .047) was the only independent factor associated with clinical failure, whereas early urinary tract drainage procedures (surgical, percutaneous, or endoscopic) were identified as protective (AOR, 0.08; 95% CI, .02-.31; P < .001). Neither univariate nor multivariate analysis showed that echinocandin therapy altered the risk of clinical failure. CONCLUSIONS: Initial echinocandin therapy was not associated with clinical failure in patients with CUTS. Notably, acute renal failure predicted worse outcomes and performing an early urologic procedure was a protective measure.
引用
- Cuervo G, Garcia-Vidal C, Puig-Asensio M, et al. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis. Clin Infect Dis. 2017. PMID: 28329281. doi:10.1093/cid/cix033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。